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ABSTRACT 
Gamma-hydroxybutyrate (GHB) is a GHB-/GABAB-receptor agonist currently used as treatment for 
narcolepsy but also as a drug of abuse. Non-medical GHB users have repeatedly reported prosexual 
effects including libido-enhancement and lowering of attractiveness standards for partner selection. 
Here, we examined the putative prosexual effects of oral GHB in healthy males in two experiments both 
employing randomized, placebo-controlled, double-blind, balanced, and cross-over study designs. In 
experiment I, subjective effects of 20 and 35 mg/kg GHB vs. placebo were tested in 32 participants using 
the Sexual Arousal and Desire Inventory. In experiment II, brain reactivity towards erotic vs. neutral 
pictures was investigated in 15 participants using functional magnetic resonance imaging after 35 mg/kg 
GHB vs. placebo. 
In experiment I, prosexual effects of GHB were shown by increased SADI ratings regarding physiological, 
evaluative, and motivational aspects of sexual arousal. In experiment II, erotic visual stimuli activated the 
bilateral insula, nucleus accumbens (NAcc), fusiform gyrus, thalamus, and left occipital pole under 
placebo. After GHB administration, even sexually neutral pictures of persons induced subjective sexual 
arousal and increased activation of the bilateral NAcc and right anterior cingulate cortex, which 
significantly correlated (left NAcc by trend). Moreover, a psychophysiological interaction analysis showed 
that GHB increased connectivity between NAcc and ventromedial prefrontal cortex during processing of 
visual erotic cues, i.e., in the condition in which subjective sexual arousal was highest. Our data show 
that GHB stimulates hedonic sexual functioning and lowers the threshold for erotic perception, which is 
related with increased susceptibility of mesolimbic reward pathways. 
 
Key words: sodium oxybate, ventral striatum, PPI, reward system, GABA, aphrodisiac, libido, date rape 
drug 
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INTRODUCTION 
Gamma-hydroxybutyrate (GHB) is an endogenous fatty acid and a metabolite of gamma-aminobutyrate 
(GABA) (Bessman and Fishbein, 1963). Due to the presence of specific G-protein coupled high and low 
affinity binding sites and the specificity of the GHB antagonist NCS-382, GHB was postulated to be a 
neurotransmitter (Benavides et al., 1982; Snead, 2000). Although the physiological role of endogenous 
GHB is still unclear, some evidence points to neuroprotective, anti-apoptotic activity (Wendt et al., 
2014). The compound binds to specific GHB- (Benavides et al., 1982) and GABAB-receptors (Engberg and 
Nissbrandt, 1993b). However, physiological concentrations of GHB seem to be insufficient to stimulate 
GABAB receptors but this mechanism is discussed to be responsible for its psychotropic effects when 
administered orally in humans (Carter et al., 2009; Engberg and Nissbrandt, 1993a). Furthermore, GHB 
has neuromodulatory properties on glutamate, dopamine, serotonin, norepinephrine, and acetylcholine 
neurotransmission (Andresen et al., 2011). Clinically, GHB is internationally approved for the treatment 
of narcolepsy and in some countries also for the treatment of alcohol withdrawal (Bosch et al., 2012).  
The drug exerts a broad spectrum of subjective effects, including sedation, stimulation, euphoria, 
disinhibition, and enhanced vitality (Bosch et al., 2015), for which the drug is instrumentalized by illicit 
users (Bosch and Seifritz, 2016). Moreover, non-medical users have repeatedly reported prosexual 
effects of the drug, including increased sexual desire and decreased sexual inhibition (Kapitany-Foveny et 
al., 2015; Lee and Levounis, 2008; Teltzrow and Bosch, 2012). Consequently, poor decision-making under 
GHB in erotic situations has been described as “lowering of sexual standards” for partner selection 
(Palamar et al., 2014). 
Neural underpinnings of sexual arousal are commonly studied using functional magnetic resonance 
imaging (fMRI) and visual erotic stimulation. Processing of visual erotic stimuli without pharmacological 
challenges was studied in depth, and identified a canonical network consisting of cognitive (anterior 
cingulate cortex [ACC], fusiform gyrus, parietal cortex, thalamus, insula), emotional (amygdala, insula), 
motivational (precentral gyrus, ACC, hypothalamus, orbitofrontal cortex [OFC], ventral striatum/nucleus 
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accumbens [NAcc]), and autonomic (ACC, hypothalamus, thalamus, insula) components (Kuhn and 
Gallinat, 2011; Stoleru et al., 2012). In contrast, putative prosexual drug effects in humans are not 
sufficiently studied so far. The indirect dopamine/noradrenaline receptor agonist methylphenidate has 
been shown to elicit prosexual effects in laboratory settings (Schmid et al., 2015; Volkow et al., 2007), 
while the exact neural correlates of these effects remain unknown. Moreover, the dopamine D2 receptor 
agonist apomorphine activates occipitotemporal areas, ACC, and NAcc (Montorsi et al., 2003), as well as 
the prefrontal cortex (PFC) (Hagemann et al., 2003) during visual erotic stimulation; however, in all of 
these studies subjective sexual arousal was not assessed.  
In order to characterize putative prosexual effects of GHB and associated neuronal underpinnings, we 
performed two experiments in healthy male volunteers. In the experiment I, subjective effects of GHB 
were assessed, using the Sexual Arousal and Desire Inventory (SADI) (Toledano and Pfaus, 2006), after 
oral administration of 20 and 35 mg/kg GHB vs. placebo in a total sample of 32 participants. In 
experiment II, neural correlates of GHB-induced (35 mg/kg GHB vs. placebo) alterations of the 
perception of erotic vs. neutral visual stimuli were studied using fMRI in 15 participants. We 
hypothesized that GHB increases sexual arousal, and that an increased activation of the above 
mentioned functional network will occur during visual erotic stimulation. 
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EXPERIMENTAL PROCEDURES 
Design and Participants 
For both experiments, a randomized, double-blind, placebo-controlled, balanced, crossed within-subject 
design was used. Participants were heterosexual, non-smoking, healthy males. Thirty-two participants 
with a mean age of 24.5 years (±3.8 SD, range 19-36), a mean verbal intelligence quotient (IQ) of 108.9 
(±14.7, 86-145), and a mean weight of 74.9 kg (±8.3, 59-96) took part in experiment one. In experiment 
two, fifteen participants with a mean age of 23.5 years (±3.6, 20-36), a mean verbal IQ of 113.4 (±18.4, 
88-145), and a mean weight of 72.2 kg (±7.4, 59-85) participated. Volunteers were recruited via online 
advertising and underwent a medical and psychiatric examination applying the Structured Clinical 
Interview for DSM-IV Axis-I Disorders (First et al., 2002). Exclusion criteria were any DSM-IV psychiatric 
disorder, neurological disorder, severe medical disease, left-handedness, and regular illegal drug use 
(lifetime use > 5 occasions, with exception of occasional cannabis use), latter assessed using the 
Interview for Psychotropic Drug Consumption (Quednow et al., 2004). Moreover, participants were 
requested to perform the Mehrfachwahl-Wortschatz-Intelligenztest (Lehrl, 2005) to estimate their verbal 
IQ. Volunteers in experiment 2 were a subsample from experiment 1. They had to abstain from drinking 
alcohol 24 h before the experiments and from drinking caffeinated beverages on the morning before and 
during the measurements. Abstinence from illegal drugs was ensured by semi-quantitative drug urine 
tests (Dimension RXL Max, Siemens, Erlangen, Germany). The study was approved by the Cantonal Ethics 
Committee of Zurich and by Swissmedic, and was registered at ClinicalTrials.gov (NCT02342366). All 
participants provided written informed consent and were financially compensated. 
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EXPERIMENT I 
Procedure 
Participants randomly received either a low (20 mg/kg, n = 16) or high dose (35 mg/kg, n = 16) of GHB 
and placebo on two test sessions separated by a seven-day interval. On the experimental days, 
participants had to fast in the morning before GHB (Xyrem® in orange juice) or placebo (salted orange 
juice) was orally administered at 9:00 am (t0 min). Experimental sessions lasted for about 225 min. 
Prosocial and neuroendocrine GHB effects were assessed and published elsewhere (Bosch et al., 2015). 
 
Measures 
Sexual Arousal and Desire Inventory 
For sexual arousal assessment, we used the German version of the SADI consisting of 53 items (Toledano 
and Pfaus, 2006), which was applied at time points: t-10 min, t+50 min, t+100 min, and t+150 min. 
Ratings are done on a 5-point Likert-scale, ranging from 0 (“does not describe it at all”) to 5 (“describes it 
perfectly”). Four scales can be derived from the SADI: evaluative, negative/aversive, physiological, and 
motivational aspects of sexual arousal and desire.  
 
EXPERIMENT II 
Procedure 
Again, GHB and placebo were applied in two sessions separated by seven days. On both test days, 
participants completed an fMRI paradigm on a Philips Achieva 3T whole-body MR-unit equipped with a 
32-channel head coil (Philips Medical Systems, Best, the Netherlands). The experiment started with a T1-
weighted anatomical brain scan, baseline resting-state (rsfMRI), and arterial spin labeling (ASL). 
Subsequently, participants were taken out of the scanner and were orally administered with a single 
dose of GHB (35 mg/kg) or placebo (t0 min). As tmax of GHB can be expected after about 40 min, the fMRI 
paradigm began at t+30 min (Liechti et al., 2016). After a post-challenge rsfMRI/ASL scan, participants 
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underwent the first run of the visual stimulation task (t+48 min). After that, another rsfMRI/ASL scan was 
performed followed by the second run of the visual stimulation (t+70 min). Subjective drug effects using 
Visual Analogue Scales (VAS) were assessed before visual stimulation (t+46 min) and after stimulation 
runs (t+55 min and t+77 min) assessing general drug effect, sedation, relaxation, arousal, euphoria, body 
sensation, emotionality, sexual arousal, dizziness, and nausea. At the end of the experiment final 
rsfMRI/ASL scans were assessed again after which participants were taken out of the scanner and 
debriefed. Experimental sessions lasted for 200 min. VAS data of the items sexual arousal, 
arousal, euphoria, general drug effect, and sedation will be presented here in relationship to the visual 
stimulation paradigm. RsfMRI/ASL and remaining VAS data are not related to the present research 
question and will therefore be published elsewhere.  
 
fMRI task 
Participants were presented either neutral or erotic pictures of women or couples during two fMRI runs 
separated by 22 min resulting in four experimental conditions: placebo/neutral, placebo/erotic, 
GHB/neutral, and GHB/erotic (Supplementary Figure 1). One run of the task consisted of a total of 50 
pictures presented for 4 s each in a blocked design (10 blocks, 20 s block duration) separated by fixation 
cross blocks (10 blocks, 20 s block duration). The pictures’ order (neutral vs. erotic) was randomized 
between sessions and participants. 
 
Data Acquisition 
Functional time series were acquired with a sensitivity-encoded single-shot echo-planar imaging 
sequence (SENSE-sshEPI)(Schmidt et al., 2005). The fMRI protocol used the following acquisition 
parameters: TE=35 ms, TR=2500 ms (=82°), FOV=24 cm, acquisition matrix = 80 x 80 interpolated to 128 x 
128, voxel size = 3 x 3 x 3 mm3, 40 contiguous axial slices (placed along the anterior-posterior 
commissure plane), and SENSE factor R = 2.0. For structural reference, a 3-dimensional T1-weighted 
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anatomical scan with the following FFE sequence was obtained: TR/TE = 9.3/4.6 ms, flip angle = 8°, 160 
sagittal slices, FOV 240 × 240 mm, voxel size = 1 × 1 × 1 mm3.  
 
DATA ANALYSIS 
SADI data were analyzed using SPSS 22.0 for Windows, applying repeated measures ANOVA with drug 
(2-fold: GHB vs. placebo) and time (4-fold) as within-subject factors and dose (2-fold: high and low dose) 
as between-subject factor. Greenhouse-Geisser correction and adjusted p-values were used in models 
with more than one degree of freedom in the numerator. Uncorrected paired t-tests were applied for 
post hoc treatment comparisons (placebo vs. GHB). Moreover, VAS data were analyzed by Bonferroni-
corrected paired t-tests (4 comparisons: placebo/neutral vs GHB/neutral, placebo/erotic vs GHB/erotic, 
placebo/neutral vs placebo/erotic, GHB/neural vs GHB/erotic). All confirmatory statistical comparisons 
were carried out at a significance level of p < .05 (two-tailed). 
Imaging data were analyzed using Statistical Parametric Mapping (SPM8; Wellcome Department of 
Cognitive Neurology, London, UK, 2009) implemented in MatLab 2012 (Mathworks Inc., Sherborn, MA). 
Slice-time correction, unwarping, realignment (b-spline interpolation) and normalization to the standard 
space of the Montreal Neurological Institute brain (MNI-brain) were performed. Smoothing was 
conducted with an isotropic 3D Gaussian filter with a full width at half maximum (FWHM) of 6 mm. 
On a first level, the functional data were analyzed using the general linear model. The four conditions 
(placebo/neutral, placebo/erotic, GHB/neutral, GHB/erotic) were modeled in a block design as separate 
regressors. The six movement parameters estimated in the preprocessing realignment step were entered 
into all first level models. The voxel-based time series was filtered with a high pass filter (time constant = 
128 s). On the group level, a 2 (drug: GHB vs. placebo) x 2 (emotion: erotic vs. neutral) ANOVA was 
computed in SPM8 to explore main and interaction effects. The threshold for whole-brain analyses was 
set to p <.001 and k > 15. Region of interest (ROI) analyses were performed with a threshold of p < .05 
(family-wise-error; FWE-corrected) and k > 5. Masks of the NAcc, the orbitofrontal cortex (OFC), the ACC, 
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the insula, the thalamus und the occipital cortex were taken from the probabilistic “Harvard Oxford 
cortical and subcortical structural atlases” provided by the Harvard Center for Morphometric Analysis (25 
% threshold)(Kennedy et al., 2016). To further explore the neural correlates of sexual arousal and GHB, 
BOLD-responses of the contrasts placebo/erotic – placebo/neutral and GHB/neutral – placebo/neutral 
and were correlated with the respective subjective sexual arousal ratings. 
Psychophysiological interaction (PPI) analysis investigates the connectivity between a seed region and 
other brain areas depending on the psychological variable (the task). The NAcc was selected as seed 
region due to its crucial impact for the processing of sexual stimuli (Kuhn and Gallinat, 2011; Stoleru et 
al., 2012). First, the eigenvariate was extracted for the NAcc as implemented in SPM8 for each session 
(placebo/neutral, placebo/erotic, GHB/neutral, GHB/erotic) separately, because it is not possible to use 
multiple sessions in a single PPI analysis. After that, the psychophysiological interaction (interaction 
term) was built by multiplying the extracted eigenvariate (physiological term) with each session 
separately (the psychological term) and convolving it with the hemodynamic response function. First-
level analyses were conducted by creating the contrasts of interest (e.g., GHB/erotic minus GHB/neutral, 
etc.) using the imagecalc procedure of SPM8 for the regressor of interest (PPI regressor). At the second 
level, we analyzed differences in connectivity between the different sessions (e.g., GHB/erotic minus 
GHB/neutral) using one-sample t-tests. Statistical corrections were identical to the previous reported 
fMRI analyses. 
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RESULTS 
EXPERIMENT I 
Sexual Arousal and Desire Inventory 
Repeated measures ANOVAs (drug[2] * time[4] * dose[2]) revealed that GHB significantly increased 
ratings in the scales physiological (drug: F[1,28] = 3.55, p = .07; time: F[3,84] = 37.2, p < .001; drug * time: 
F[3,84] = 9.56, p < .001), evaluative (time: F[3,84] = 31.7, p < .001; drug * time: F[3,84] = 7.87, p < .001), 
and motivational (time: F[3,84] = 22.4, p < .001; drug * time: F[3,84] = 5.28, p < .01) aspects, while the 
scale negative/aversive aspects did not differ (time: F(3,84) = 1.60, p = .21; drug * time: F(3,84) = 1.47, p 
= .24) compared to placebo. Uncorrected post hoc t-tests confirmed significant drug effects at t+50 min 
for the subscales evaluative, and motivational, and at t+100 min for the scale physiological aspects. As 
we did not find significant main effects for the factor dose (p > .25) on SADI measures, doses are shown 
pooled in Figure 1. 
 
- Figure 1 - 
 
EXPERIMENT II 
Subjective Measures 
After visual stimulation (t+55 min and t+77 min were pooled), we found that general drug effect and 
sedation clearly discriminated GHB and placebo conditions (Bonferroni-corrected paired t-tests: 
t(18)=5.94-6.91, p < .001) (Figure 2a,b). Moreover, there was an increase of arousal and euphoria over 
the four conditions (placebo/neutral<placebo/erotic<GHB/neutral<GHB/erotic) (Figure 2c,d). GHB clearly 
increased sexual arousal during watching both neutral pictures (t(18) = 4.03, p < .01) and erotic (t(18) = 
3.22, p < .05) (Figure 2e). Additionally, watching erotic pictures increased the sexual arousal under 
placebo (t(18) = 4.70, p < .001) as well as under GHB (t(18) = 5.19, p < .001), validating the sexual 
stimulation paradigm (Figure 2e). 
 
- Figure 2 - 
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Neuroimaging 
Because the aim of the study was to explore the impact of GHB on the BOLD-response, we conducted 
whole-brain analyses as well as ROI-analyses and computed the main effect of GHB and interaction 
effects. We analyzed the contrast between erotic and neutral pictures in the placebo condition 
(erotic>neutral under placebo: placebo/erotic) and found increased activations in the erotic as compared 
to the neutral condition in the bilateral insula, bilateral NAcc, bilateral thalamus, bilateral fusiform gyrus, 
and left occipital pole (see Table 1; Figure 3). In response to neutral pictures, GHB (GHB>placebo in 
neutral condition: GHB/neutral) elicited significant BOLD response increases in the right ACC and 
bilateral NAcc (see Table 1; Figure 4). Most interesting, we found an interaction effect in our ROI-
analyses, showing significantly increased BOLD-responses to the bilateral NAcc in the contrast 
GHB/neutral as compared to the placebo/neutral condition (Figure 4c). In contrast, no increased 
activation could be found in the opposite contrast placebo/neutral >GHB/neutral. The comparison of 
GHB>placebo in the erotic condition (GHB/erotic) revealed no significant changes. However, a PPI 
analysis of the GHB effect on the perception of erotic and neutral pictures revealed an increased task-
related functional connectivity between NAcc and the ventromedial PFC (vmPFC) (p < .05, FWE-
corrected) under the influence of the drug (Figure 5). Moreover, correlating BOLD-responses with sexual 
arousal ratings revealed significant positive correlations between sexual arousal and increased BOLD-
responses in the contrast placebo/erotic – placebo/neutral in the left (x/y/z= -6/14/-2; z= 3.12, p = .02, 
FWE-corrected) and right (x/y/z= 6/14/-2; z= 2.99, p= .03, FWE-corrected) NAcc as well as the 
orbitofrontal cortex (x/y/z= -28/30/-18; z= 4.31, p= .009, FWE-corrected). In the same vein, sexual 
arousal also positively correlates with BOLD-responses in the contrast GHB/neutral – placebo/neutral in 
the right (x/y/z= 12/16/-4; z= 2.81, p= .05, FWE-corrected) NAcc, the ACC (x/y/z= 14/44/10; z= 4.08, p= 
.03, FWE-corrected) as well as a marginal trend in the left NAcc (x/y/z= -8/18/-2; z= 2.5,  p= .09, FWE-
corrected). 
- Figures 3, 4, 5 -  
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DISCUSSION 
To our knowledge, the present study is the first investigating the neural effects of GHB using 
neuroimaging techniques. Our results demonstrate that GHB in fact has prosexual effects in healthy 
males as the drug increased subjective sexual arousal with and without visual erotic stimulation, 
respectively. In a sexual stimulation fMRI paradigm, erotic pictures under placebo (placebo/erotic) 
elicited sexual arousal and increased BOLD signals in a neuronal network including the bilateral insula, 
NAcc, thalamus, fusiform gyrus, and left occipital pole, as expected. Sexual arousal positively correlated 
with BOLD signals in NAcc and orbitofrontal cortex in this condition. While the combination of GHB and 
erotic pictures (GHB/erotic) did not result in BOLD changes compared to placebo/erotic, we found an 
increased task-related functional connectivity between the NAcc and the left vmPFC in this condition. 
However, after GHB intake, the bilateral NAcc as well as the ACC were activated already by sexually 
neutral pictures of females (GHB/neutral), which significantly correlated with increased subjective sexual 
arousal measured with the VAS (left NAcc by trend). Thus, increased hedonic sexual drive and enhanced 
erotic perception of neutral stimuli induced by GHB seems to be mediated by increased reactivity of the 
mesolimbic reward system. 
Pleasures of food, sex, and drugs of abuse produce highly overlapping patterns of mesolimbic reward 
system activation, including the prefrontal cortex, insula, ACC, NAcc, and ventral pallidum (Berridge and 
Kringelbach, 2015). They are understood to serve adaptive functions by motivating an individual to 
pursue rewards necessary for fitness. Hedonic gain of function may occur, when the susceptibility of the 
reward system for erotic or other stimuli is pharmacologically increased. As such, GHB used as a club 
drug, was reported to increase sexual feelings and to “lower sexual standards” for partner selection 
(Palamar et al., 2014). Here, in experiment I, GHB increased sexual arousal, resulting in elevated ratings 
in the SADI-scales physiological, evaluative, and motivational aspects of sexual arousal and desire (Figure 
1a-c). Moreover, visual stimulation with erotic, but also with neutral pictures of females increased VAS 
for sexual arousal after GHB intake (Figure 2e). Reports of sexual enhancing effects of psychostimulants 
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were recently confirmed by two experimental studies administering methylphenidate (Schmid et al., 
2015; Volkow et al., 2007). The prosexual effects of psychostimulants have been attributed to their 
capacity to increase dopamine concentrations in the mesolimbic reward system involving dopaminergic 
neurons in the ventral tegmental area (VTA) that innervate the NAcc, amygdala, and the vmPFC 
(Frohmader et al., 2010). On the contrary, GHB is a mixed GHB-/GABAB agonist but its behavioral effects 
are mediated mostly by GABAergic mechanisms when exogenously applied (Carter et al., 2009). The only 
GABAergic drug previously discussed as potentially prosexual is alcohol. However, animal and human 
data have shown opposite effects: sexual disinhibition of low and sexual inhibition of high doses of 
alcohol (Frohmader et al., 2010). Nevertheless, GHB also has downstream effects on the 
neurotransmission in the mesolimbic dopamine system (Snead and Gibson, 2005). In the substantia nigra 
and striatum of rats the occurrence of markers for GHB synthesis indicates GHBergic control of 
presynaptic dopaminergic activity (Hedou et al., 2000). However, it is a matter of debate if GHB enhances 
(Cruz et al., 2004) or inhibits (Brancucci et al., 2004) dopaminergic output in terminal regions, and if 
these effects are mediated by GABAB- or GHB-receptors. Converging evidence points to a dose- and time-
dependent bi-directional effect of GHB on mesolimbic dopamine release (Hechler et al., 1991). Lower 
doses seem to indirectly disinhibit dopaminergic VTA neurons, while increasing doses additionally 
directly inhibit dopaminergic neurons (Labouebe et al., 2007).  
In line with these preclinical findings, erotic pictures in the placebo condition, as well as neutral and 
erotic pictures in the GHB condition elicited subjective sexual arousal and activated neuronal networks 
related to sexual arousal and reward processing in our participants (Figures 2-5). The networks identified 
here, highly correspond to a canonical sexual-cue processing circuit previously described in the meta-
analyses of Kuhn and Gallinat (2011) and Stoleru et al (2012). Specifically, our patterns cover cognitive 
(ACC, fusiform gyrus, thalamus, insula), emotional (insula), motivational (ACC, ventral striatum/NAcc), 
and autonomic (ACC, thalamus, insula) components of sexual arousal outlined by these authors. While 
activations in the placebo/erotic condition could be found in widespread regions confirming earlier 
14 
 
results in this field, GHB-related alterations were specifically located in areas pertaining to the 
mesolimbic reward system such as the ACC, NAcc, and vmPFC. In fact, the dopamine D2 receptor agonist 
apomorphine, which is used as second-line treatment for erectile dysfunction, also increased activity in 
the ACC (Hagemann et al., 2003) and NAcc (Montorsi et al., 2003) in response to visual erotic 
stimulation. Unfortunately, subjective sexual arousal has not been assessed in this investigation. In our 
study, subjects under the influence of GHB perceived neutral pictures as sexually arousing, which was 
correlated with increased activity in the ACC and NAcc compared to placebo.  
It has been proposed that the ACC mediates motivational aspects of behavior, including sexual arousal, 
by modulating reward processing through its projections to the NAcc (Sesack and Grace, 2010; Sewards 
and Sewards, 2003). It is regarded as a key structure in the processing of the initiation, persistence, and 
seeking of sexual reward (Frohmader et al., 2010). In humans, the ACC is crucial for the processing of 
emotional valence of erotic stimuli (Walter et al., 2008). Moreover, reduced ACC responsiveness to 
erotic stimuli was found under medication with paroxetine, which was paralleled by increased subjective 
ratings of sexual dysfunction (Abler et al., 2011). In another fMRI study, resting-state functional 
connectivity reductions of the amygdala with the ACC, dopaminergic midbrain, and insula predicted the 
occurrence of paroxetine-induced sexual dysfunction, whereby ACC connectivity was correlated with 
impaired sexual satisfaction (Metzger et al., 2013).  
Showing a close functional relationship with the ACC, the NAcc is a converging node for cortical (ACC, 
vmPFC) and subcortical (VTA) projections, playing an essential role in selecting hedonic motivated 
behaviors (Sesack and Grace, 2010). NAcc activity is seen as the neural representation of direct reward 
and reward anticipation (Ponseti et al., 2006; Walter et al., 2008). As such, it forms part of the above 
mentioned sexual-cue related networks, and was directly associated with the degree of perceived sexual 
arousal in two studies (Redoute et al., 2000; Walter et al., 2008). On the contrary, reduced NAcc 
responses to reward are correlated with state anhedonia in patients with depression (Pizzagalli et al., 
2009; Wacker et al., 2009) and healthy subjects (Keller et al., 2013). The ROI-based analysis of the NAcc 
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in our subjects showed that all conditions that induced sexual arousal also increased NAcc activity 
(GHB/erotic only by trend, Figure 4).  
As expected, the condition GHB/erotic led to the highest levels of self-described sexual arousal. While no 
BOLD changes occurred in this condition compared to placebo, we found an increased task-related 
functional connectivity between NAcc and left vmPFC using PPI analysis (Figure 5). Recently, a growing 
recognition for task-related functional connectivity changes has been established in psychiatric research 
(Admon et al., 2015; Cisler et al., 2014; Steuwe et al., 2015), also in absence of direct BOLD alterations 
(Esslinger et al., 2009). A majority of the neural afferents to the NAcc originates from vmPFC, by which 
behavioral drives, mood states, direct or anticipated reward shape consecutive behaviors (Sesack and 
Grace, 2010). Interestingly, NAcc-PFC functional connectivity is reduced by dopaminergic drugs such as 
methylphenidate (Ramaekers et al., 2013) and pramipexole (Ye et al., 2011) in healthy subjects, pointing 
to a differential effect of these substances and GHB on brain reward circuits. The increased task-related 
functional connectivity in the NAcc-vmPFC pathway, together with the GHB-induced enhancement of 
ACC and NAcc activity demonstrates a pronounced susceptibility of mesolimbic reward pathways 
towards hedonic stimuli under influence of the drug. Because of this, enhancement of ACC and NAcc 
activity might be a useful biomarker to assess GHB effects on hedonic/sexual functioning, including 
potential therapeutic implications for depression treatment and resolution of antidepressant-related 
sexual dysfunction (Bosch et al., 2012; Bosch and Seifritz, 2016). 
Our study bears a number of limitations: the sample size was low and limited to heterosexual male 
subjects. The latter was owed to the decision to start with one gender and one sexual orientation first. 
Moreover, due to limited funding we only used one dose in experiment II. Moreover, effectivity of 
blinding was not systematically assessed, and questionable due to recognizable subjective drug effects. 
Further studies assessing prosexual effects of GHB should explore gender-, sexual orientation-, and dose-
dependent effects, and consider the use of an active placebo to reduce probability of unblinding. 
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In summary, our primary finding is that GHB induces subjective sexual arousal and lowers the threshold 
for erotic perceptions probably by altering the reactivity of mesolimbic brain networks. Thus, under GHB, 
even non-erotic stimuli can induce sexual arousal and a sexual-cue related brain activation pattern 
including ACC and NAcc. Additionally, the drug increases NAcc-vmPFC functional connectivity during 
processing of visual erotic cues, which was paralleled by the highest scores of subjective sexual arousal.  
The study therefore confirms at an objective, controlled, and experimental level the reports of 
recreational users that GHB leads to enhanced sexual arousal and less selective sexual partner choice. 
The observed prosexual effects are most likely induced by GHB- and/or GABAB-receptor-mediated 
disinhibition of VTA neurons, resulting in increased dopamine release in the NAcc, ACC, and vmPFC. 
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Tables 
Table 1 Peak MNI coordinate regions with significant BOLD signal changes (p<0.05, FWE-corrected, k=15) 
Peak MNI coordinate regions Laterality Cluster size Laterality (MNI) zmax pcorr Figure 
 X Y Z  
Erotic > neutral in the placebo condition 
 
Insula 
L 23 -36 -4 16 3.86417 0.0144199 
3a 
Insula 
R 378 38 -8 0 3.47669 0.0499014 
Nucleus Accumbens 
L 31 -6 14 -2 2.94016 0.0265744 
3b 
Nucleus Accumbens 
R 40 6 14 -4 2.74202 0.0442265 
Thalamus 
L 422 -16 -14 4 3.69614 0.023752 
3c 
Thalamus 
R 400 12 -12 2 3.95807 0.00974635 
Fusiform Gyrus 
L 476 -40 -66 -10 4.61506 0.0006029 
3d 
Fusiform Gyrus 
R 307 42 -64 -12 3.97446 0.00666532 
Occipital Pole 
L 257 -32 -90 22 4.40386 0.00753929 3e 
 
GHB > placebo in the neutral condition 
 
Anterior Cingulate Cortex 
R 534 2 26 16 3.98933 0.0178517 4a 
Nucleus Accumbens 
L 18 -10 18 -4 3.18159 0.0135556 
4b 
Nucleus Accumbens 
R 34 12 18 -4 2.91162 0.0286576 
 
GHB > placebo in the erotic condition 
 
No significant changes found         
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Figure Legends 
Fig. 1: Ratings (means and SEM) of the scales physiological (a), evaluative (b), motivational (c), and 
negative/aversive (d) aspects of the Sexual Arousal and Desire Inventory (SADI) after GHB 
compared to placebo. Paired t-tests (uncorrected): *p<.05, **p<.01. 
Fig. 2: Visual analogue scale (VAS) ratings after visual stimulation task (t+55min and t+77min were 
pooled) in the conditions placebo/neutral, placebo/erotic, GHB/neutral, and GHB/erotic: a) 
general drug effect, b) sedation, c) arousal, d) euphoria, and e) sexual arousal. Paired t-tests 
(Bonferroni-corrected): *p<.05, **p<.01, ***p<.001. 
Fig. 3: Axial BOLD response whole-brain map of the contrast placebo/erotic – placebo/neutral 
(placebo/erotic condition): a) insula, b) nucleus accumbens, c) thalamus, d) fusiform gyrus, e) 
occipital pole (p<.05, FWE-corrected, k=15).  
Fig. 4: BOLD response whole-brain map of the contrast GHB/neutral – placebo/neutral (GHB/neutral 
condition): a) anterior cingulate cortex, b) nucleus accumbens (p<.05, FWE-corrected, k=15), and 
c) region of interest (ROI) BOLD signal comparison of the four assessed conditions in the nucleus 
accumbens (*=p<.05, FWE-corrected). 
Fig. 5: Psychophysical Interaction of GHB and erotic pictures on task-related connectivity of nucleus 
accumbens with left ventromedial prefrontal cortex (*=p<.05, FWE-corrected). 
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